Evidence map›Paper›PMID 33303736›Full record

ArticleTranslational psychiatry2020

Involvement of NMDA receptors containing the GluN2C subunit in the psychotomimetic and antidepressant-like effects of ketamine.

Mireia Tarrés-Gatius, Lluís Miquel-Rio, Leticia Campa, Francesc Artigas, Anna Castañé

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. A combination of ΔNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Article
  6. Discovery of GluN2A subtype-selectiveActa pharmaceutica Sinica. B · 2024
    Review
  7. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mireia Tarrés-GatiusInstitut d'Investigacions Biomèdiques de Barcelona (IIBB-CSIC), Barcelona, Spain.
Lluís Miquel-RioInstitut d'Investigacions Biomèdiques de Barcelona (IIBB-CSIC), Barcelona, Spain.
Leticia CampaInstitut d'Investigacions Biomèdiques de Barcelona (IIBB-CSIC), Barcelona, Spain.
Francesc ArtigasInstitut d'Investigacions Biomèdiques de Barcelona (IIBB-CSIC), Barcelona, Spain.
Anna CastañéInstitut d'Investigacions Biomèdiques de Barcelona (IIBB-CSIC), Barcelona, Spain. castaneanna@gmail.com.ORCID 0000-0002-2578-445X
Instituto de Salud Carlos III · ESUniversitat de Vic - Universitat Central de Catalunya · ES

Funding

GI PROTEIN MEDIATED LOCALIZATION OF B2-AR SIGNALING IN RAT CARDIOMYOCYTESZ01AG000285 · NIA · AGING · PI KUSCHEL, M · 1998 to 1998
–
Generalitat de Catalunya (Government of Catalonia) 2014-SGR798Generalitat de Catalunya (Government of Catalonia) 2016FI-B00285Generalitat de Catalunya (Government of Catalonia) 2017-SGR717Ministerio de Economía y Competitividad (Ministry of Economy and Competitiveness) PI16/00287Ministerio de Economía y Competitividad (Ministry of Economy and Competitiveness) SAF 2015-68346-PMinisterio de Economía y Competitividad (Ministry of Economy and Competitiveness) SAF2015-68346-PMinistry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CIBERSAM
6 · The paper itself

Abstract

Acute ketamine administration evokes rapid and sustained antidepressant effects in treatment-resistant patients. However, ketamine also produces transient perceptual disturbances similarly to those evoked by other non-competitive NMDA-R antagonists like phencyclidine (PCP). Although the brain networks involved in both ketamine actions are not fully understood, PCP and ketamine activate thalamo-cortical networks after NMDA-R blockade in GABAergic neurons of the reticular thalamic nucleus (RtN). Given the involvement of thalamo-cortical networks in processing sensory information, these networks may underlie psychotomimetic action. Since the GluN2C subunit is densely expressed in the thalamus, including the RtN, we examined the dependence of psychotomimetic and antidepressant-like actions of ketamine on the presence of GluN2C subunits, using wild-type and GluN2C knockout (GluN2CKO) mice. Likewise, since few studies have investigated ketamine's effects in females, we used mice of both sexes. GluN2C deletion dramatically reduced stereotyped (circling) behavior induced by ketamine in male and female mice, while the antidepressant-like effect was fully preserved in both genotypes and sexes. Despite ketamine appeared to induce similar effects in both sexes, some neurobiological differences were observed between male and female mice regarding c-fos expression in thalamic nuclei and cerebellum, and glutamate surge in prefrontal cortex. In conclusion, the GluN2C subunit may discriminate between antidepressant-like and psychotomimetic actions of ketamine. Further, the abundant presence of GluN2C subunits in the cerebellum and the improved motor coordination of GluN2CKO mice after ketamine treatment suggest the involvement of cerebellar NMDA-Rs in some behavioral actions of ketamine.

Indexed as

KetamineAnimalsAntidepressive AgentsFemaleGABAergic NeuronsHumansMaleMicePhencyclidineReceptors, N-Methyl-D-AspartateAntidepressive AgentsKetaminePhencyclidineReceptors, N-Methyl-D-Aspartate

Identifiers

PMID33303736
PMCPMC7729946
OpenAlexW3110685581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.